TY - JOUR
T1 - GLP-1 and Intestinal Diseases
AU - Hunt, Jenna Elizabeth
AU - Holst, Jens Juul
AU - Jeppesen, Palle Bekker
AU - Kissow, Hannelouise
PY - 2021/4/5
Y1 - 2021/4/5
N2 - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1's influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
AB - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1's influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
UR - http://www.scopus.com/inward/record.url?scp=85104635466&partnerID=8YFLogxK
U2 - 10.3390/biomedicines9040383
DO - 10.3390/biomedicines9040383
M3 - Review
C2 - 33916501
SN - 2227-9059
VL - 9
SP - 383
JO - Biomedicines
JF - Biomedicines
IS - 4
M1 - 383
ER -